Sellas Vaccine Extends Survival in Blood Cancer Trial, Shares Surge
Sellas Life Sciences reported that its experimental vaccine, galinpepimut-S, extended survival in a late-stage trial for acute myeloid leukemia (AML) patients. The 126-patient study showed a 41% reduction in death risk, with median survival of 24 months vs. 14.7 months for the control group. Sellas shares surged over 300% to $22.93, potentially adding $3.1B to its market value. The company plans to discuss an accelerated FDA approval strategy.
How this was made
The 30-second read
Why it matters
The trial’s reported risk reduction and median survival extension are material clinical endpoints, and management’s stated intent to pursue an accelerated FDA filing in 1H 2027 provides a near-term regulatory catalyst.
Market read
A clinically meaningful late-stage survival result plus a stated accelerated filing timeline is likely to drive sustained repricing and heightened volatility in SLS.
What to watch
Key risks include confirmatory trial requirements, manufacturing/scale-up for a personalized or immune-priming vaccine approach, and whether WT1-targeting efficacy holds across broader AML subgroups.
Background
Sellas Life Sciences is developing galinpepimut-S (GPS), an experimental vaccine targeting WT1-positive residual leukemia cells in AML patients in remission who cannot receive transplant.
Ticker impact
Sellas Life Sciences reports late-stage AML vaccine GPS cut death risk 41% and extends median survival to 24 months, driving a record one-day share surge.
Likely continued upside bias as traders price in expedited approval odds and a 2027 filing timeline, though volatility may persist on regulatory and confirmatory-data risk.
The article discloses specific trial outcomes (risk reduction, median survival), a large same-day move (shares more than tripled), and a concrete plan to meet the FDA for accelerated filing in 1H 2027.
Market effects
Strengthens sentiment for oncology immunotherapy and vaccine platforms, potentially lifting peer interest in AML maintenance/relapse strategies.
Primarily US biotech sentiment, with global investors repricing risk for late-stage oncology programs.
May influence international expectations for AML treatment paradigms and accelerated approval pathways for immunotherapies.
Counterpoint
Even with a survival benefit, traders may discount durability, generalizability, and the chance that regulators require additional evidence beyond accelerated pathways.
Key entities
- companySellas Life Sciences
Developer of the GPS vaccine for AML, reporting late-stage trial survival benefit and planning FDA accelerated filing.
- productGalinpepimut-S (GPS)
Experimental AML vaccine designed to train the immune system to attack WT1-carrying leukemia cells.
- regulatorUS FDA
Regulatory body Sellas plans to meet to discuss an accelerated approval filing strategy.

